Evidence map›Paper›PMID 34668104›Full record

ArticleMolecular diversity2022

Benzyl-para-di-[5-methyl-4-(n-octylamino) pyrimidin-2(1H)one] as an interferon beta (IFN-β) modulator.

Lena Trifonov, Mariya Yurchenko, Astrid Skjesol, Guy Cohen, Terje Espevik, Edward E Korshin, Lene Melsæther Grøvdal, Harald Husebye, Arie Gruzman

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Lena Trifonov *Department of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, 5290002, Ramat-Gan, Israel.
Mariya Yurchenko *Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Astrid SkjesolCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Guy CohenThe Skin Research Institute, The Dead-Sea & Arava Science Center, 86910, Masada, Israel.
Terje EspevikCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Edward E KorshinDepartment of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, 5290002, Ramat-Gan, Israel.
Lene Melsæther GrøvdalCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway.
Harald HusebyeCentre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491, Trondheim, Norway. harald.husebye@ntnu.no.
Arie GruzmanDepartment of Chemistry, Faculty of Exact Sciences, Bar-Ilan University, 5290002, Ramat-Gan, Israel. gruzmaa@biu.ac.il.ORCID http://orcid.org/0000-0002-8006-4201
Norwegian University of Science and Technology · NOBar-Ilan University · ILDead Sea and Arava Science Center · IL

Funding

Israeli Ministry of Science and Technology 580458776Israel Ministry of Immigration and Integration 8279Israel Ministry of Industry, Trade, and Labor 56324Research Council of Norway 223255/F50Research Council of Norway 275876
6 · The paper itself

Abstract

IFN-β is a cytokine that plays a significant role in the immune system. Inhibition of IFN-β might be used as a therapeutic approach to treat septic shock. A peptidomimetic previously developed by our research team, 1-benzyl-5-methyl-4-(n-octylamino)pyrimidin-2(1H)-one (LT87), was used as an cardioprotective agent in a myocardial ischemia (MI) mouse model. We have developed new LT87 derivatives by synthetizing its dimers in an attempt to extend its structural variety and enhance its biological activity. A dimeric derivative, LT127, exhibited a dose-dependent inhibition of LPS-mediated IFN-β and subsequent CXCL10 mRNA transcription. The effect was selective and transduced through TLR4- and TRAM/TRIF-mediated signaling, with no significant effect on MyD88-dependent signaling. However, this effect was not specific to TLR4, since a similar effect was observed both on TLR8- and MDA5/RIG-I-stimulated IFN-β expression. Nevertheless, LT127 might serve as a drug candidate, specifically as an inhibitor for IFN-β production in order to develop a novel therapeutic approach to prevent septic shock.

Indexed as

Interferon-betaPeptidomimeticsShock, SepticAnimalsCytokinesMiceSignal TransductionToll-Like Receptor 4CytokinesInterferon-betaPeptidomimeticsToll-Like Receptor 4CXCL10Interferon-βPyrimidine derivativesTLRTNF

Identifiers

PMID34668104
OpenAlexW3207153080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.